RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $18

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and raises the price target from $17 to $18.